INTRODUCTION
Cigarette smoke particulate matter (PM) is genotoxic in vitro (1) . Novel tobacco materials can reduce PM genotoxicity (1). Accurate estimation of the reduction of genotoxicity requires quantitative interpretation of the results. We demonstrated previously that a 30% difference between tobacco smoke particulate matter genotoxicity could be detected in the Ames test and the mouse lymphoma assay (2, 3). The aim of this poster is to recommend statistical methods for the quantitative interpretation of the Ames test, IVMNT and MLA; and the number of replicate cultures per dose in the IVMNT, when comparing cigarette smoke PMs.
METHODS

Test article preparation
3R4F, a 'US style' blended reference cigarette was used in this study. The PM was generated by conditioning the cigarettes for a minimum of 48 hours at 22±1°C and 60±3% relative humidity (ISO 3402:1999) and smoked on a RM200 smoking machine using ISO standard puffing parameters (35cm 3 puff volume, taken over 2 seconds, every 60 seconds; ISO 3308:2000) . An appropriate number of cigarettes were smoked to obtain up to 300mg of PM on a 44mm Cambridge filter pad. The pads were weighed before and after smoking to determine the weight of PM deposited, and the PM was then eluted in DMSO to a concentration of 24mg/ml and stored protected from light at -80°C.
In vitro micronucleus test (IVMNT)
The IVMNT was performed as in (1), at Covance Laboratories Ltd., Harrogate, according to OECD guidelines. Briefly, replicate V79 cell cultures in Dulbecco's minimal essential medium, supplemented with 10% foetal calf serum and 0.52% penicillin/streptomycin, were pulsed with test samples for 3 h followed by a 21 h recovery, without S9.
Duplicate slides were scored for cytotoxicity and micronucleated binucleate (MnBn) cells. Data are plotted as the means of replicate cultures +/-standard error of the mean (SEM), within each experiment.
Statistical methods
Transformed data were tested for linearity and significance as shown in Fig. 1 . The linear portion of the response was identified by fitting a generalised linear model with linear and quadratic terms for dose. If the quadratic term was significant (p<0.01), the same model was fitted again with the highest dose excluded, continuing until the quadratic term was not significant or no less than three doses remained. Significant differences were identified using analysis of covariance (ANCOVA) (slope and magnitude) or t-tests (common doses). Prior to the t-test, Ames test and IVMNT data were rank-transformed; MLA data were also ranktransformed, if there was evidence of heterogeneity (Levene's test). Resolving power was calculated using standard formulae. 
Replicate cultures
The intra-assay variabilities in twenty-seven historical in vitro micronucleus studies were reviewed, for an initial estimate of the number of replicate cultures per dose, to resolve different PMs. The review concluded that the 3 hour exposure without S9 was the treatment most sensitive to PM, and with this treatment, approximately six replicate cultures per dose would resolve PMs. This estimate was tested empirically. A detectable difference of 30% was achieved with four replicate cultures per dose (Table 1) . To confirm the resolving power of four replicate cultures per dose, two PMs were compared. These were both 3R4F PM, from the same stock solution, but one sample was diluted to 70% (v/v), to simulate a 30% difference between PMs. Statistically significant (p ≤ 0.01) and dose-related increases in the proportion of MnBn were observed for both samples (Fig. 2) . The responses were different, and the difference was statistically significant (Table 2) . Table 2 Confirmation of the resolving power of IVMNT for different PMs * significantly lower than 3R4F PM, p< 0.01 In this common statistical approach to the three in vitro methods, dose responses are compared as slopes, intercepts or at common doses, depending on the linearity of the responses. The linear part of the dose response is identified statistically, using adaptations for the Poisson, binomial and normal distributions of Ames test, MLA and IVMNT data respectively. The distributions of residual errors were consistent with these methods.
The linear portion of the curve was used to compare the slopes of dose responses. A test for difference in slopes was investigated using an ANCOVA model containing terms for dose, PM and the PM-by-dose interaction term. Where PM-by-dose was significant (p<0.05), the difference in slopes was statistically significant. This was the case for most of the historical data on different PMs, used to evaluate significance tests. Occasionally, linear dose responses were parallel (PM-by-dose p≥0.05). The PM samples were then compared for differences in overall magnitudes. This was done by subjecting data pooled across doses to ANCOVA, with dose as a covariate and a term for PM as a fixed effect. Where the PM term was significant (p<0.05), the difference in magnitudes was statistically different.
There were also some data-sets where a linear part of the dose response could not be established for one or both of the PM samples. In this case, different PMs were compared at each common dose using t-tests, two-sided at the 5% level of significance.
This approach has simplified the implementation of statistical comparisons of different PMs in these genotoxicity tests, and can accommodate occasional nonlinear responses.
